PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19735690-4 2009 The reasons for these curves are still unclear, but since these drugs can also activate TRPV1 receptors and increase glutamate release, we hypothesized that, at high doses, cannabidiol and WIN 55,212-2, a CB1 receptor agonist, could activate TRPV1 receptors, facilitating glutamate neurotransmission and anxiety responses. Cannabidiol 173-184 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 88-93 23924692-2 2013 By contrast, cannabidiol (CBD), a phytocannabinoid with a broad therapeutic profile, is generally presented as an example of a cannabinoid compound with no motor effects due to its poor affinity for the CB1 and the CB2 receptor, despite its activity at the TRPV1 receptor. Cannabidiol 13-24 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 257-262 23924692-2 2013 By contrast, cannabidiol (CBD), a phytocannabinoid with a broad therapeutic profile, is generally presented as an example of a cannabinoid compound with no motor effects due to its poor affinity for the CB1 and the CB2 receptor, despite its activity at the TRPV1 receptor. Cannabidiol 26-29 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 257-262 20942863-1 2011 BACKGROUND AND PURPOSE: Two non-psychoactive cannabinoids, cannabidiol (CBD) and cannabichromene (CBC), are known to modulate in vitro the activity of proteins involved in nociceptive mechanisms, including transient receptor potential (TRP) channels of vanilloid type-1 (TRPV1) and of ankyrin type-1 (TRPA1), the equilibrative nucleoside transporter and proteins facilitating endocannabinoid inactivation. Cannabidiol 59-70 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 271-276 20942863-1 2011 BACKGROUND AND PURPOSE: Two non-psychoactive cannabinoids, cannabidiol (CBD) and cannabichromene (CBC), are known to modulate in vitro the activity of proteins involved in nociceptive mechanisms, including transient receptor potential (TRP) channels of vanilloid type-1 (TRPV1) and of ankyrin type-1 (TRPA1), the equilibrative nucleoside transporter and proteins facilitating endocannabinoid inactivation. Cannabidiol 72-75 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 271-276 19735690-4 2009 The reasons for these curves are still unclear, but since these drugs can also activate TRPV1 receptors and increase glutamate release, we hypothesized that, at high doses, cannabidiol and WIN 55,212-2, a CB1 receptor agonist, could activate TRPV1 receptors, facilitating glutamate neurotransmission and anxiety responses. Cannabidiol 173-184 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 242-247 18550765-5 2008 We also demonstrated that cannabidiol evoked a concentration-dependent release of calcitonin gene-related peptide (CGRP) from cultured rat dorsal root ganglion neurons in a cannabinoid receptor- and TRPV1-independent manner. Cannabidiol 26-37 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 199-204 15313881-0 2004 Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Cannabidiol 98-109 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 10-15 31178718-0 2019 Cannabidiol Affects the Bezold-Jarisch Reflex via TRPV1 and 5-HT3 Receptors and Has Peripheral Sympathomimetic Effects in Spontaneously Hypertensive and Normotensive Rats. Cannabidiol 0-11 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 50-55 15140635-0 2004 Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats. Cannabidiol 0-11 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 32-35 15140635-9 2004 We conclude that there are substantial functional differences between human and rat vanilloid VR1 receptors with respect to the actions of cannabidiol as an agonist at vanilloid VR1 receptors. Cannabidiol 139-150 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 94-97 15140635-9 2004 We conclude that there are substantial functional differences between human and rat vanilloid VR1 receptors with respect to the actions of cannabidiol as an agonist at vanilloid VR1 receptors. Cannabidiol 139-150 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 178-181 11606325-0 2001 Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Cannabidiol 22-33 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 83-86 11606325-8 2001 Both CBD and (+)-CBD, but not the other analogues, stimulated VR1 with EC(50)=3.2 - 3.5 microM, and with a maximal effect similar in efficacy to that of capsaicin, i.e. 67 - 70% of the effect obtained with ionomycin (4 microM). Cannabidiol 5-8 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 62-65 11606325-8 2001 Both CBD and (+)-CBD, but not the other analogues, stimulated VR1 with EC(50)=3.2 - 3.5 microM, and with a maximal effect similar in efficacy to that of capsaicin, i.e. 67 - 70% of the effect obtained with ionomycin (4 microM). Cannabidiol 13-20 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 62-65 11606325-9 2001 CBD (10 microM) desensitized VR1 to the action of capsaicin. Cannabidiol 0-3 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 29-32 11606325-19 2001 These findings suggest that VR1 receptors, or increased levels of endogenous AEA, might mediate some of the pharmacological effects of CBD and its analogues. Cannabidiol 135-138 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 28-31 34274349-0 2021 Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: Possible role of CB1 and TRPV1 receptors. Cannabidiol 0-11 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 157-162 32982390-3 2020 Hence, we conducted in vitro studies, to elucidate the efficacy and mechanisms of CBD for inhibiting neuronal hypersensitivity in cultured rat sensory neurons, following activation of TRPV1. Cannabidiol 82-85 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 184-189 32982390-14 2020 Conclusion: CBD at low doses corresponding to plasma concentrations observed physiologically inhibits or desensitizes neuronal TRPV1 signalling by inhibiting the adenylyl cyclase - cAMP pathway, which is essential for maintaining TRPV1 phosphorylation and sensitization. Cannabidiol 12-15 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 127-132 32982390-14 2020 Conclusion: CBD at low doses corresponding to plasma concentrations observed physiologically inhibits or desensitizes neuronal TRPV1 signalling by inhibiting the adenylyl cyclase - cAMP pathway, which is essential for maintaining TRPV1 phosphorylation and sensitization. Cannabidiol 12-15 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 230-235 31437433-0 2020 Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-TH1A and TRPV1 receptor mechanisms. Cannabidiol 0-11 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 83-88 31178718-10 2019 The CBD-induced fall in HR but not in BP was diminished by the TRPV1 receptor antagonist capsazepine and almost completely abolished if CBD was re-injected after previous administration. Cannabidiol 4-7 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 63-68 31178718-14 2019 Conclusions: Cannabidiol (1) induces the Bezold-Jarisch reflex likely via TRPV1 receptors (which undergo tachyphylaxis) more markedly in SHR than in WKY; (2) inhibits the Bezold-Jarisch reflex induced by activation of 5-HT3 but not TRPV1 receptors; (3) has peripheral sympathomimetic, (4) vasodilatory, and (5) negative inotropic effects. Cannabidiol 13-24 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 74-79 31178718-14 2019 Conclusions: Cannabidiol (1) induces the Bezold-Jarisch reflex likely via TRPV1 receptors (which undergo tachyphylaxis) more markedly in SHR than in WKY; (2) inhibits the Bezold-Jarisch reflex induced by activation of 5-HT3 but not TRPV1 receptors; (3) has peripheral sympathomimetic, (4) vasodilatory, and (5) negative inotropic effects. Cannabidiol 13-24 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 232-237 30157131-11 2019 Overall, repeated treatment with low-dose CBD induces analgesia predominantly through TRPV1 activation, reduces anxiety through 5-HT1A receptor activation, and rescues impaired 5-HT neurotransmission under neuropathic pain conditions. Cannabidiol 42-45 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 86-91